Citigroup - Mylan "buy"

21,425 € +1,06% +0,225 €
Frankfurt ,buran  

http://www.ariva.de/news/...ess-Checklist-to-Holiday-Planning-4383769  

of Qualaquin® Capsules

15:45 18.12.12

PR Newswire

PITTSBURGH, Dec. 18, 2012

PITTSBURGH, Dec. 18, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quinine Sulfate Capsules USP, 324 mg. This product is the generic version of Mutual Pharmaceutical Company, Inc.'s Qualaquin® Capsules, and is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria.(1)

Quinine Sulfate Capsules USP, 324 mg, had U.S. sales of approximately $31.9 million for the 12 months ending Sept. 30, 2012, according to IMS Health. Mylan has begun shipping this product.

Currently, Mylan has 178 ANDAs pending FDA approval representing $79.2 billion in annual sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

(1) Quinine Sulfate Capsules are not approved for the treatment or prevention of nocturnal leg cramps and use for such treatment may result in serious and life-threatening hematologic reactions, including thrombocytopenia and hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP).  Chronic renal impairment associated with the development of TTP has been reported.

SOURCE Mylan Inc.
Quelle: PR Newswire  

Canonsburg, PA 15317, USA
buran  

http://www.ariva.de/news/...-Distributed-by-Mylan-Institution-4386896  

Mylan Announces Comtan® Settlement Agreement

14:55 20.12.12

PR Newswire

PITTSBURGH, Dec. 20, 2012

PITTSBURGH, Dec. 20, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has entered into a settlement agreement with Orion Corporation that will resolve patent litigation related to Entacapone Tablets, 200 mg. Entacapone Tablets are the generic version of Orion's Comtan®, indicated as an adjunct to levodopa/carbidopa therapy to treat patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".

Under the terms of the settlement agreement, Mylan may launch a generic version of Comtan, 200 mg, on April 1, 2013, at the earliest. Pursuant to the agreement, pending litigation will be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Entacapone Tablets, 200 mg, had U.S. sales of approximately $104.9 million for the 12 months ending Sept. 30, 2012, according to IMS Health.

This press release includes statements that constitute "forward-looking statements," including with regard to the settlement of the litigation and sales of the product. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: any legal or regulatory challenges to the settlement; strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.
Quelle: PR Newswire  

Frankfurt  

Spanne 27,49 -  27,78 ,top  

wer denn möchte ..Preisliste bitte selbst entnehmen ,GrB  

Nasdaq sind 125.822 shares durch ..zu sehen waren bereits: 27,62 USD ..geht voll klar hier ..buran  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  28.12.12     27,17     27,40§26,91 26,92 $ 3.418.732 92,4 M
nun wieder mehr Druck nach oben  

http://www.ariva.de/news/...nches-Generic-Nordette-28-Tablets-4391505  

http://www.ariva.de/news/...-First-Generic-Maxalt-MLT-Tablets-4393119

....RT +1,09% ,GrB  

Handelsplatz Letzter Veränderung Vortag letzte Stk. Tag-Stk. Kursspanne Zeit
 Tradegate§21,17  € +1,72% 20,81 € 238 238 21,17 -  21,17 10:06:15  

 

Datum Erster Hoch Tief Schluss     Stücke Volumen
  03.01.13     27,62     27,75§27,53 27,62 $ 3.249.848 89,8 M  

nicht verwechseln mit Tradegate ..Geschulte- und Kennerblicke sehen das auch ohne mein Kommentar ..buran danke und weitermachen  

Zeit    Kurs Stück
  09:46:49§21,55 € 100
  08:04:32§21,335 € 95
___________________
DAX-Tafel: 7.741 Zählerpunkte
GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
10.01.13 28,28 28,60 28,22  28,25 $ 4.754.470 122 M
09.01.13 27,83 28,22 27,765  28,03 $ 3.778.630 102 M  

319.444 sind bereits durch 28,455 angetastet ..and gooooo  

28,51 voll aufgeblendet in USD  

geht voll klar bis hier ..3.219.693 Stücke gepeitscht ..buran und MfG  

wenn's geht in einem Paket ohne Teilausführungen ..2.490.111 Stücke sind bereits geschachert worden ..zu sehen waren am Ticker stattliche 28,05 USD GLÜCKWUNSCH  

und noch nie einen Wunsch und Traum mit meine Mylan verworfen

Zeit  Kurs  Stück  
10:11:19 21,21 €  100  
10:11:09 21,21 €  300

Tradegate ..buran  

Cliffs Natural Resources, Tesoro, Dick's Sporting Goods, and Mylan Laboratories Released By InvestorsObserver15:35 16.01.13


PR Newswire

CHICAGO, Jan. 16, 2013

CHICAGO, Jan. 16, 2013 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LVS, CLF, TSO, DKS, and MYL.

(Logo: http://photos.prnewswire.com/prnh/20120712/CG39046)

To see what our analysts have discovered about these stocks read the InvestorsObserver's PriceWatch Alerts at http://www.investorsobserver.com/pr/11520130 (Note: You may have to copy this link into your browser then press the [ENTER] key.)

Today's PriceWatch Alerts cover the following stocks: Las Vegas Sands (NYSE: LVS), Cliffs Natural Resources (NYSE: CLF), Tesoro (NYSE: TSO), Dick's Sporting Goods (NYSE: DKS), and Mylan Laboratories (Nasdaq: MYL).

InvestorsObserver's PriceWatch Alerts contain concise, detailed strategies for each stock we cover, including position protection tactics designed to defend investors from potential market shifts. While many other market reports only provide stock news and opinion, we offer strategies that can bulwark investments against uncertainty and increase chances of making a profit, even if a stock goes down.

"We go above and beyond typical market coverage," said Bobby Raines, Analyst at InvestorsObserver. "Trading experts and beginning investors alike can find value in our PriceWatch Alerts. We provide actionable strategies that protect investments with basic hedging tactics, along with a concise explanation of our techniques."

For essential information on stocks poised to move go to:

http://www.investorsobserver.com/pr/11520130 for InvestorsObserver's PriceWatch Alerts.

InvestorsObserver.com is an online newsletter which focuses on the U.S. equities and options markets. Our analytical tools, screening techniques, rigorous research methods and committed staff provide solid information to help subscribers make the best possible investment decisions. For more information go to www.investorsobserver.com.

All stocks and options shown are examples only-- not recommendations to buy or sell. Our picks do not represent a positive or negative outlook on any security.  Potential returns do not take into account your trade size, brokerage commissions or taxes--expenses that will affect actual investment returns. Stocks and options involve risk, thus they are not suitable for all investors. Prior to buying or selling options, a person should request a copy of Characteristics and Risks of Standardized Options available at http://www.cboe.com/Resources/Intro.aspx. Privacy policy available upon request.

SOURCE InvestorsObserver


Quelle: PR Newswire